Opaleye Management Inc. 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Opaleye Management Inc. disclosed 41 US equity positions worth $494.1m in its Q2 2025 13F filing. The largest position was HROW at 24.1% of the reported book, followed by ETON and IMNM. Against the Q1 2025 filing, it opened 5 new positions, added to 14 and reduced 12 among the top 41 holdings.
What did Opaleye Management Inc. own in Q2 2025? Top 41 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | HROW HARROW HEALTH INC | 24.1% | $119.3m | 3,905,000 | -1% | reduced | |
| 2 | ETON ETON PHARMACEUTICALS INC | 8.2% | $40.8m | 2,860,000 | 0% | held | |
| 3 | IMNM IMMUNOME INC | Healthcare | 6.6% | $32.8m | 3,529,581 | -1% | reduced |
| 4 | SANUWAVE HEALTH INC | 6.5% | $32.2m | 980,000 | 1% | added | |
| 5 | LQDA LIQUIDIA CORPORATION | Healthcare | 6.2% | $30.8m | 2,475,000 | 10% | added |
| 6 | CDXS CODEXIS INC | Healthcare | 6.2% | $30.7m | 12,600,000 | 33% | added |
| 7 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 6.1% | $30.0m | 475,000 | -3% | reduced |
| 8 | TGTX TG THERAPEUTICS INC | Healthcare | 3.9% | $19.3m | 535,000 | 0% | held |
| 9 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 3.0% | $14.8m | 1,595,000 | 0% | held |
| 10 | ARVN ARVINAS INC | Healthcare | 2.5% | $12.4m | 1,680,000 | -15% | reduced |
| 11 | LRMR LARIMAR THERAPEUTICS INC | Healthcare | 2.4% | $11.9m | 4,110,000 | 115% | added |
| 12 | IRON DISC MEDICINE INC | Healthcare | 2.0% | $9.9m | 186,418 | 119% | added |
| 13 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 1.7% | $8.6m | 500,000 | – | new |
| 14 | VIGL VIGIL NEUROSCIENCES INC | 1.6% | $8.0m | 1,000,000 | – | new | |
| 15 | CGON CG ONCOLOGY INC | Healthcare | 1.4% | $6.9m | 266,000 | 62% | added |
| 16 | XOMA CORP DEL | 1.3% | $6.4m | 255,087 | 1% | added | |
| 17 | EWTX EDGEWISE THERAPEUTICS INC | 1.3% | $6.4m | 490,000 | 24% | added | |
| 18 | STOK STOKE THERAPEUTICS INC | Healthcare | 1.3% | $6.4m | 562,120 | 87% | added |
| 19 | ANIK ANIKA THERAPEUTICS INC | Healthcare | 1.3% | $6.2m | 588,797 | 49% | added |
| 20 | GOSSAMER BIO INC | 1.2% | $5.9m | 11,500,000 | 0% | held | |
| 21 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.2% | $5.8m | 105,000 | 0% | held |
| 22 | DNA GINKGO BIOWORKS HOLDINGS | 1.1% | $5.6m | 500,000 | -58% | reduced | |
| 23 | KARYOPHARM THERAPEUTICS INC | 0.9% | $4.6m | 6,000,000 | 0% | held | |
| 24 | GOSS GOSSAMER BIO INC | Healthcare | 0.9% | $4.4m | 3,545,000 | -17% | reduced |
| 25 | RZLT REZOLUTE INC | 0.8% | $4.0m | 903,442 | 94% | added | |
| 26 | RVMD REVOLUTION MEDICINES INC | Healthcare | 0.8% | $3.9m | 105,000 | – | new |
| 27 | EPIEUR ESSA PHARMA INC | 0.8% | $3.8m | 2,209,998 | 0% | held | |
| 28 | CRGX CARGO THERAPEUTICS INC | 0.6% | $2.7m | 666,503 | 0% | held | |
| 29 | MBX MBX BIOSCIENCES INC | Healthcare | 0.6% | $2.7m | 239,319 | -4% | reduced |
| 30 | ZYME ZYMEWORKS INC | Healthcare | 0.5% | $2.6m | 210,000 | 20% | added |
| 31 | TARA PROTARA THERAPEUTICS INC | 0.5% | $2.6m | 855,000 | -51% | reduced | |
| 32 | ALMS ALUMIS INC | 0.5% | $2.3m | 775,000 | – | new | |
| 33 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 0.5% | $2.2m | 1,924,300 | -3% | reduced |
| 34 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.4% | $2.1m | 390,000 | -51% | reduced |
| 35 | RCEL AVITA MEDICAL INC | 0.4% | $2.1m | 389,519 | -11% | reduced | |
| 36 | IRD OPUS GENETICS INC | 0.2% | $1.1m | 1,220,000 | 4% | added | |
| 37 | DERM JOURNEY MEDICAL CORP | 0.1% | $682.1k | 95,000 | 37% | added | |
| 38 | ELEVATION ONCOLOGY INC | 0.1% | $529.4k | 1,442,061 | – | new | |
| 39 | IBIO IBIO INC | 0.1% | $285.0k | 375,000 | 0% | held | |
| 40 | PEPG PEPGEN INC | Healthcare | 0.1% | $266.4k | 240,000 | -43% | reduced |
| 41 | ADGM ADAGIO MED HLDGS INC | 0.0% | $143.7k | 110,571 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.